Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment

Wieser, Jill K; Kuehn, Gina J.; Prezzano, James C.; Cusick, Elizabeth; Stiegler, Julia D.; Scott, Glynis; Liesveld, Jane L.; Beck, Lisa A.

doi:10.1016/j.jdcr.2020.02.030

Cited by 14 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, pruritus in both atopic and nonatopic individuals has been reported to improve with dupilumab for various types of chronic refractory itch, such as lichen planus, genital itching, uremic itching, idiopathic itching, and eosinophilic dermatosis of hematological malignancies [160][161][162]. In addition, isolated case reports show the beneficial effect of dupilumab in various skin disorders and diseases affecting the skin, such as eosinophilic annular erythema (with the resolution of all lesions and pruritus [164,165]), keloids [166], pruritic epidermolysis bullosa [167], hypereosinophilic syndrome [168], and cutaneous T-cell lymphoma (mycosis fungoides) [169].…”

Section: Pruritusmentioning

confidence: 99%

Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido¹,

Moreno²,

Dávila³

2022

J Investig Allergol Clin

View full text Add to dashboard Cite

Recent advances in understanding T2 inflammation have broadened the diseases in which T2 inflammation can be involved. Dupilumab is a recently developed monoclonal antibody blocking the signaling of both IL-4 and IL13, two crucial cytokines of the T2 responses. New possible indications are increasingly exploring. Among them are skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome, among other several cutaneous diseases. Also, respiratory diseases, such as allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis. In addition, eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis, and food allergy are two more research fields. Here we review the published data and clinical trials about the use of dupilumab in these disorders.

show abstract

Section: Pruritusmentioning

confidence: 99%

Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido¹,

Moreno²,

Dávila³

2022

J Investig Allergol Clin

View full text Add to dashboard Cite

show abstract

“…Case reports and small series using alemtuzumab, [12][13][14][15] dupilumab, 16 and omalizumab [17][18][19] have also demonstrated benefit in the treatment of some patients with HES. Unfortunately, to date there are no published studies comparing biologics for the treatment of HES, and there are limited data to guide the biologic choice for the different HES subtypes or even optimal dosing.…”

Section: Hes Subgroup Ihesmentioning

confidence: 99%

An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes

Chen¹,

Roufosse²,

Wang³

et al. 2022

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

“… 1 Recently, dupilumab was reported to be markedly effective and well tolerated in a treatment-recalcitrant patient with hypereosinophilic syndrome (HES). 2 …”

Section: Introductionmentioning

confidence: 99%